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Abstract 
 Public health and the improvement of human health has been a topic of interest for 
centuries – even more so in current society. Preventative healthcare, specifically, has become a 
focus in recent years. Vaccines are one of the primary methods in which health officials attempt 
to improve both individual and collective human health before any issues even arise. That is why 
it is imperative to take into account any factors that may impede the ability of vaccines to 
perform to their full capacity. This includes the presence – or lack thereof – of certain hormones, 
like estrogen. Obesity has also been shown to have a negative effect on antibody response to the 
flu vaccine (Sheridan et al.). Post-menopausal women have been shown to be especially 
susceptible to numerous health related consequences like obesity (Colombel et al.) and decline in 
immune responses, which can possibly be attributed to estrogen deprivation (Gameiro et al.).  
This association is further supported by a mouse model study by Nguyen et al. which showed 
hormone replacement therapy to have a positive effect on antibody response to the influenza 
vaccine in post-menopausal mice. Because a decline in estrogen is thought to possibly be the 
cause of a declined antibody response to the flu vaccine in the mouse model, we hypothesized 
that post-menopausal women with less estrogen will have a decreased antibody response to the 
2014-2015 H1N1 flu vaccine. Furthermore, though obese post-menopausal women have been 
shown to have higher levels of estrogen than non-obese post-menopausal women – opposite 
trend of pre-menopausal women (Freeman et al.) – we additionally hypothesized that obese post-
menopausal women will also have a decreased immune response to the 2014-2015 H1N1 flu 
vaccine. To test these hypotheses, we collected pre and 30 days post influenza vaccine serum 
samples from twenty-four post-menopausal. Enzyme-linked immunosorbent assays (ELISA) 
were conducted on the pre- and post-vaccination serum samples and their antibody responses and 
estrogen levels were assessed and compared. As expected, mean estrogen concentrations 
increased with increasing BMI categorization. Additionally, overweight post-menopausal women 
had a greater mean antibody response as opposed to healthy weight or obese post-menopausal 
women. However, this data was not significant. Though this data was not significant, it should be 
repeated with a larger sample size and with second blood draws done more than 30 days post-
vaccination. Another potential expansion of this study is to include data from pre-menopausal 
women, as well, since there may be more variations in estrogen in their serum. 
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Introduction 
What is menopause? 
 Menopause is formally known as the cessation of production of oestrogen and 
progesterone which happens when the ovarian follicle store is finally depleted (Nelson et al. 
2001). The transition to menopause occurs around mid-to-late 40’s and can greatly affect 
women’s lives, though the exact effects vary from woman to woman. Historically, menopause 
has not been thoroughly studied, leaving many questions unanswered and creating a passive 
attitude towards symptoms associated with menopause. Rather than try to remediate some of the 
severe symptoms associated with menopause, such as immune system decline and osteoporosis, 
many women fall prey to thinking that the symptoms are normal and that they must live with 
them – which is not true. There are numerous new therapies and studies that show that it is 
possible to improve the symptoms of menopause. One of the main effects of concern associated 
with menopause and lower estrogen levels is a decline in immune function (Gameiro et al. 2010), 
indicating a decreased antibody response to the annual flu vaccine in post-menopausal women. 
Estrogen and its forms 
Estrogen concentrations in the body vary throughout stages of the menstrual cycle, as well as 
throughout a woman’s life, depending on the reproductive stage she is at. There are three forms 
present in the body: Estrone (E1), Estradiol (E2), and Estrol (E3). Estrone is the most produced 
form of estrogen in the body post-menopausally; however, it is also the weakest. It is produced 
by the ovaries and fat tissue (ESTROGEN).  Estradiol is the strongest form of estrogen (both pre 
and post menopausally). Though Estrone (E1) is the form most produced post-menopause, the 
decline of estradiol is what causes the dramatic changes in the body that women experience 
during menopause. Estradiol is the most commonly clinically measured among the three forms of 
estrogen. Estradiol levels of 50 pg/mL is considered low for pre-menopausal women. During the 
first 2-5 years of menopause (transition), however, that value drops to 25-35 pg Estradiol/mL 
until it eventually dips below 25 pg estradiol/mL (ESTROGEN). Estrol (E3) is the weakest of the 
three forms and is actually a waste product of estradiol. It is what is responsible for morning 
sickness in pregnant women. It is 8% as potent as estradiol and 14% as potent as estrone 
(ESTROGEN). 
The various types of antibodies 
 There are five immunoglobulin classes that play a role in the human body, but 
immunoglobulin G (IgG) is the most commonly found in human serum and accounts for 10-20% 
of plasma protein (Vidarsson et al. 2014). Immunoglobulins are glycoproteins that are composed 
of 82-96% protein and 4-18% carbohydrates. There are four subclasses of IgG: IgG1, IgG2, 
IgG3, and IgG4, with IgG1 being the most abundant subclass and IgG4 being the least abundant 
subclass (Vidarsson et al. 2014). The type of secondary immune response and the type and 
composition of the antigen entering the body determines the body’s response to any health threat. 
IgG1 is mainly induced by membrane proteins and soluble protein antigens and is often 
accompanied by IgG3 and IgG4. Antibodies combine antigen binding sites with innate receptors’ 
and adaptor molecules’ binding sites to trigger effector mechanisms of the innate immune system 
(Vidarsson et al. 2014). For the purposes of this study, IgG total and IgG1 pre-and post-
vaccination serum levels were analyzed. 
Obesity in postmenopausal women 
 Colombel et. Al. (1997) demonstrated that there is a positive correlation between increase 
in age and increased weight gain, more greatly in women than in men. It was also shown that this 
increase in weight reached a peak after 50 years of age. Another study by the name of “Healthy 
Women’s Study”, mentioned by Colombel,  found that while there is an increase in weight gain 
with increasing age, this relationship is independent of menopausal status. The study divided 
women into three groups: pre-menopausal (who were still premenopausal by the end of the 
study), transitional menopausal, and post-menopausal. Some women from the latter group were 
also either undergoing or had already undergone hormone replacement therapy. These women 
were studied for three years. By the end of the three years, the increase in weight gain with 
increasing age was found to be significant in all three of the above mentioned groups 
(Colombel), indicating the lack of a relationship between menopausal status and weight gain in 
women. There is speculation, however, that there is a relationship between redistribution of fat 
post-menopause and menopausal status, causing an increase in abdominal fat in post-menopausal 
women (Colombel). The exact cause, however, is unclear. 
The role of estrogen in health decline 
 A recent review of studies led to the conclusion that though age also plays a factor, 
estrogen deprivation may be the cause of immune changes in post-menopausal women (Gameiro 
et al. 2010). This review included both human and animal studies via an electronic search on 
MEDLINE and the Cochrane Controlled Clinical Trials Register and identified 688 studies 
involving the immune system and menopause, of which 30 studies were selected. 
Immunosenescence, a “decline in immune function and immune response that occurs with 
aging” (“What is immunosenescence”), is potentially thought to be associated with higher rates 
of infection and disease (Gameiro et al. 2010). For some of these diseases, this could potentially 
be due to increases in IL-6 and other pro-inflammatory markers that increase in the bodies of 
post-menopausal women as a result of decreased estrogen levels (Gameiro et al. 2010). Some 
studies also showed that hormone replacement therapy (or the ending of hormone replacement 
therapy) also produced changes in the immune system (Gameiro et al. 2010).  
The role of obesity in the response to influenza infection 
 Mouse models utilizing diet-induced obesity and influenza infection have demonstrated 
that obesity results in decreased immunity and increased morbidity and mortality from influenza 
(Smith et al. 2007). As with estrogen deprivation, obesity has also been associated with an 
increase in IL-6 and other pro-inflammatory responses of the body. Studies in humans 
demonstrated similar effects to the animal model. Sheridan et al, (2012). Antibody levels to 
influenza vaccination were analyzed at prevaccination, 30 days and 1 year post influenza 
vaccination. The results found a significant positive correlation between BMI and higher initial 
fold increase in IgG antibody response 1 month post vaccination. However, the results changed 
12 months post vaccination – an association was discovered between high BMI and a decrease in 
antibody titer. This indicates that obesity does indeed impair antibody response, a relationship 
which could be dependent on time of vaccination, as well.  
Mouse model with influenza infection and estrogen levels 
 Post-menopausal women are included among the world’s more susceptible people, which 
is why it is unfortunate that there are so few studies regarding their response to influenza virus 
and/or vaccine. A study by Doan Nguyen used a mouse model to study the effects of menopause 
and estrogen levels on the body’s response to the flu vaccine. An inactivated vaccine from the 
A/New Caledonia/20/99 (H1N1) strain was given to mice that were ovariectomized (OVEX), 
OVEX with estradiol replacement (OVEX+E2), and sham-OVEX. The results of the study found 
that the mice from the latter two groups responded more significantly to the vaccine than the 
OVEX group, indicating that ovariectomy negatively affects immune response (Nguyen). This 
shows a potential negative effect via menopause on the antibody response, as well. Additionally, 
since mice in the OVEX+E2 group responded as significantly as mice in the sham-OVEX group, 
it is also potentially indicative of the importance of estrogen (specifically, estradiol) on the 
antibody response to the flu vaccine. As of 2011, when this study was published, there had not 
been any human studies looking into the effects of estradiol on antibody response to the 
influenza vaccine (Nguyen et al.). 
Summary  
 There seems to be a well-established relationship between menopause and weight gain, 
weight gain and immune system impairment, and menopause and immune system impairment. 
Thus, I hypothesize that post-menopausal women with higher estradiol levels at initial blood 
draw will have higher antibody response to the influenza vaccine, while post-menopausal women 
with lower estradiol levels will have lower antibody response to the influenza vaccine. 
Additionally, I also hypothesize that post-menopausal women with greater BMI’s will have a 
lower antibody response to the influenza vaccine, while post-menopausal women with lower 
BMI’s will have a higher antibody response to the influenza vaccine. 
 
 
 
 
Methods 
Serum Sample Collection 
 Annually, the Beck Lab collects blood samples from about 500 patients pre-influenza 
vaccination and 30 days post-influenza vaccination. The participants are financially compensated 
for their effort and donation. The blood is processed via PBMC isolation and serum samples are 
obtained from the blood samples. From these yearly-obtained samples, I chose 55 women from 
three groups from the women who participated in the 2014-2015 vaccination and blood draws: 
pre-menopausal, post-menopausal, and post-menopausal with hormone replacement therapy. 
However, due to the fact that the data had not initially been controlled for the fact that estrogen 
levels can vary throughout the month for pre-menopausal women, including pre-menopausal 
women was not possible. Due to the fact that only 5 women were found to have had hormone 
replacement therapy post-menopause, it was not possible to include that group either. Thus, this 
study focused on 24 post-menopausal women who were between the ages of 40 and 60 years old, 
with varying BMI’s, and had not had any hormone replacement therapy. Since estradiol decline 
is responsible for the changes in women’s bodies post-menopause, the estradiol levels of the 24 
women pre-vaccination were analyzed. Additionally, the IgG1 and IgG total antibody levels of 
the 24 women were also analyzed. These values were then compared to each other and to the 
women’s BMI’s. The demographics of the women chosen for this study are shown in the chart 
below:  
 Antibody ELISA 
 In order to assess the IgG total and IgG1 antibody response to the influenza vaccine, an 
indirect enzyme-linked immunosorbent assay (ELISA) will be used to analyze the pre- and post-
vaccination serum samples of each of the 24 women involved in the study using a protocol 
previously designed in Beck Lab. ELISAs make it possible to bind specific antibodies needed for 
analysis (ENZYME). There are different types of ELISAs that can be performed, some of which 
are shown in the figure below:  
 
For the purposes of this study, two different antibodies were assessed via indirect ELISAs. These 
antibodies were IgG total and IgG1. The procedure begins by diluting the Influenza A/California 
(H1N1) vaccine strain(1:160 for IgG1 and 1:80 for IgG total) and coating each well in a 96-well 
plate with 31.25 µL of the dilution. The plate is then kept overnight in a 4 degrees Celsius 
refrigerator in a ziplock bag with a moist paper towel in order to keep the wells from drying out. 
The following day, the wells are blocked with 200 µL of block buffer (nonfat dry milk, PBS, 
Na2CO3 and NaHCO3) and incubated at 37 degrees for one hour. During this incubation time, 
each of the 48 serum samples (24 patients’ pre- and post-vaccination samples) was diluted (1:800 
for IgG1 and 1:25600 for IgG total) with dilution buffer (nonfat dry milk and PBS). After the 
one-hour incubation was over, the plates were washed with PBSt to wash away any 
nonspecifically bound materials and 50 µL of each of the dilution samples was put into its own 
respective well in triplicates with controls and blanks in each plate. Each plate fit the triplicates 
of 30 samples total, not including the control and blank samples, so a total of two plates were 
used. After putting in the diluted serum samples, the plates were incubated at 37 degrees Celsius 
for 2 hours. Afterwards, the plates were then washed again and 50 µL of a 1:1000 dilution of 
goat anti-human IgG conjugated to horseradish peroxidase in dilution buffer were added to each 
well and incubated for another hour at 37 degrees Celsius. The plates were then again washed 
and 100 µL of TMB substrate solution mix were added to each plate and allowed to incubate at 
room temperature for 30 minutes. The reaction was then stopped with 100 µL of 2M Sulfuric 
Acid. The absorbance of the samples in the plates was then read in a plate reader at 450 nm. 
Estrogen ELISA 
 In order to assess pre-vaccination estradiol in the 24 women, a pre-coated AChE 
competitive ELISA kit from the company “Cayman Chemical” (item no. 582251) was used. The 
ELISA was performed following the instructions in the pamphlet that came with the kit. Below is 
a summary of the procedure: 
 The table below shows the layout of the plates. The serum samples this time were analyzed in 
duplicates. The last column was left blank, while the second and third columns were used to 
analyze the standard in order to covert the absorbance values to concentrations. Only one plate 
was necessary, since only the pre-vaccination estradiol levels were assessed. 
HAU/HAI 
 A hemaglutination assay (HAI) was also carried out to measure the antibody response of 
the women to the vaccine. The influenza virus has a surface protein called the hemagglutinin that 
binds to erythrocytes to form a “lattice”, a property called “hemagglutination” (Acharya). When 
these hemagglutinins react, they form agglutinated cells that irregularily settle in the wells of the 
plates used for the assay (Acharya). Unagglutinated cells form a “button” on the bottom of the 
well, as explained in the figure below:  
(Acharya) 
 
 
In an HAI, if antibodies to the virus being studied are present, the virus will not be able to attach 
to the RBC, thereby preventing hemagglutination (Acharya). An HAI titer is the highest dilution 
of serum that prevents hemagglutination (Acharya). Hemagglutination will be present in all of 
the cells if the antibody is not present. However, if the antibodies are present, it will be at the 
point at which the antibodies are diluted properly (Acharya). The highest dilutions of serum are 
interpreted using the dilution standard values shown in the figure below: 
 (Acharya) 
The serum samples must all be treated with receptor destroying enzyme (RDE) prior to 
performing the assay in order to prevent complications by any nonspecific inhibitors of 
hemagglutination that may be present in the sample. This process was begun by adding 30 µL of 
each patients serum sample to 1.5 mL tubes under sterile conditions. 90 µL of RDE were then 
added to each and the samples were allowed to incubate overnight at 37 degrees Celsius. The 
following day, the samples were then heat inactivated for an hour and allowed to cool at room 
temperature. 180 µL of physiological saline were then added to the samples, which were then 
allowed to freeze for at least four hours prior to use. The final dilution of the serum samples was 
1:10. On the day that the HAI was to be done, an HAU was also performed. 2-4mL of turkey 
blood were added to a conical tube and 10 mL of PBS were mixed in prior to centrifuging for 10 
minutes at 4C, 270g, and 5 decelaration. The supernatant was then poured off and another 10 mL 
of PBS were added prior to centrifuging again. This was repeated one more time. After the last 
time, the size of the RBC pellet was estimated and enough DPBS was added to yield a 0.5% 
packed RBC suspension. 180µL of PBS were then added to the first row of a 96 well-bottom 
plate, while 100µL were added to the rest of the plate. 20µL of virus were added to the first row 
of the plate, except for wells 11 and 12 (negative controls). A serial dilution was then performed 
on the plate. 50µL of each well were then transferred to their respective wells on a V-bottom 
plate and 50µL of the 0.5% RBC suspension were added to each well. The highest dilution of 
virus causing complete agglutination was observed and was indicated to contain 1 HAU/0.05 mL 
(meaning that 8HAU/50µL is the HAU titer). In order to test the diluted virus, 200 µL of  of the 
8HAU/50µL virus were added to columns 1-10 while 11 and 12 again served as the negative 
control. 200µL of PBS were added to 11 and 12. 100µL of PBS were added to all of the other 
wells and a serial dilution was again performed. The samples were again transferred to a V-
bottom plate and the 0.5% RBC suspension was again added to each well as done previously. 
The plate was again incubated at room temperature and observed for hemagglutination. Once the 
diluted virus passed the test, it was okay to move onto the actual HAI procedure. Twelve plates 
were run with 4 samples on each plate (2 patients’ pre- and post-vaccination serum samples) 
using the layout shown below:  
 
The previously RDE treated serum was thawed in a water bath and stored on ice until it was 
ready to use. 25µL of PBS were added to all wells except for the first row. 50µL of serum 
sample were added to the first eight columns (4 samples total with duplicates for each), and the 
rest of the first row was filled with 50 µL of positive control, negative control, diluted virus, and 
PBS, respectively. A serial dilution was performed on the entire plate. 25µL of the diluted virus 
were then added to all of the wells in columns 1-10 and 25µL of PBS were added to columns 11 
and 12. The plates were then incubated for 15 minutes, after which 50µL 0.5% RBC suspension 
was added to each well. The plate was then incubated for 20 minutes and observed for 
hemagglutination. An example of one of these plates is shown below: 
  
 
Results:  
 In this study, 24 women’s isolated pre- and post-vaccination serum samples from the 
2014-2015 study were used to test the above stated hypothesis. For this study, an indirect ELISA, 
a competitive ELISA, and a HAI were all performed on the 48 total samples. The women were 
grouped in various ways but were primarily grouped by BMI. A summary of this data and the 
data from the various tests performed is shown in the table below.  
BMI 
Category 
Mean 
BMI 
Estradiol 
(pg/ml) 
IgG total Mean 
Percent 
Change 
IgG1 
Mean 
Percent 
Change 
HAI 
titer 
MFI 
Healthy 21.3 5.463396 19.94403 14.9043 5.81 
Overweight 28.4 5.551467 50.43823 93.7402 2 
Obese 37.5 6.181821 -10.1922 40.4567 5.82 
 
 
The relationship between BMI and antibody response 
As previously stated, an ELISA was performed on the 48 samples in order to measure the 
amount of IgG total and IgG1 antibody present in each sample, and the percent difference of the 
pre- and post-vaccination serum samples was calculated in order to assess the antibody response 
in each patient to the vaccine. The percent difference is the 30-days post-vaccination serum 
antibody reading minus the pre-vaccination serum antibody reading, times 100. An HAI titer 
antibody response was also assessed. The fold increase of each patient was calculated by 
dividing the 30-days post-vaccination serum antibody reading value by the pre-vaccination 
serum antibody value. A one-way ANOVA was used to analyze the significance between BMI 
and antibody response, shown below. 
 Figure 1. The graph above shows the one-way ANOVA test assessing the relationship between 
BMI and IgG total antibody response. The p-value for this data was 0.5102 with a R-square 
value 0.06207, indicating no significance and weak correlation.  
 Figure 2. The graph above shows the one-way ANOVA test assessing the relationship between 
BMI and IgG1 antibody response. The p-value for this data was 0.1737 with a R-square value 
0.1535, indicating no significance and weak correlation.   
 Figure 1. The graph above shows the one-way ANOVA test assessing the relationship between 
BMI and HAI titer antibody response. The p-value for this data was 0.6776 with a R-square 
value 0.03639, indicating no significance and weak correlation.   
 
The relationship between estradiol serum concentration and antibody response 
 The concentration of estradiol present in each woman’s serum sample was also measured 
via a competitive ELISA kit. In this case, however, the pre-vaccination sample was assessed for 
estradiol concentration rather than pre- and post-vaccination. The significance of the relationship 
between initial estradiol serum concentration and antibody response (IgG total, IgG1, and HAI 
titer) was also tested via a one-way ANOVA. The women were grouped by estradiol 
concentrations. Group 1 included women with estradiol concentrations of 0.0 to 3.0 pg/mL; 
group 2 included women with estradiol concentrations of 3.1 to 8 pg/mL; and group 3 included 
women with estradiol concentrations of 8.1 pg/mL and above. 
  
 
 
Figure 1. The graph above shows the one-way ANOVA test assessing the relationship between 
initial estradiol serum concentrations and IgG total antibody response. The p-value for this data 
was 0.1284 with a R-square value 0.1776, indicating no significance and weak correlation.   
 Figure 1. The graph above shows the one-way ANOVA test assessing the relationship between 
initial estradiol serum concentrations and IgG total antibody response. The p-value for this data 
was 0.3417 with a R-square value 0.0972, indicating no significance and weak correlation.   
 Figure 1. The graph above shows the one-way ANOVA test assessing the relationship between 
initial estradiol serum concentrations and IgG total antibody response. The p-value for this data 
was 0.0765 with a R-square value 0.2172, indicating no significance and weak correlation. 
A linear regression was also run on the relationship between estradiol serum concentration and 
IgG total antibody response, IgG1 antibody response, and HAI titer antibody response, shown 
below: 
 Figure 1. The graph above shows a linear regression test assessing the relationship between 
initial estradiol serum concentrations and IgG total antibody response. The p-value for this data 
was 0.0586 with a R-square value 0.1531, indicating no significance and weak correlation. 
 
Figure 1. The graph above shows a linear regression test assessing the relationship between 
initial estradiol serum concentrations and IgG1 antibody response. The p-value for this data was 
0.5062 with a R-square value 0.2034, indicating no significance and weak correlation. 
  
 
Figure 1. The graph above shows a linear regression test assessing the relationship between 
initial estradiol serum concentrations and HAI titer antibody response. The p-value for this data 
was 0.1237 with a R-square value 0.1043, indicating no significance and weak correlation. 
 
Since all of the above tests came back insignificant and some of them were very close to 
having a p-value of 0.05 significance, a two-way ANOVA was also performed on the 
relationship between BMI and HAI titer, estradiol and HAI titer, and, finally, age and HAI titer 
in order to assess the real cause behind any significance in antibody response. The women were 
grouped a little differently this time in order to account for the small sample size. In the first two-
way ANOVA, the women were grouped into nonobese and obese. The nonobese category 
included women with BMI’s less than 30 kg/m^2, while the obese category included women 
with BMI’s greater than 30 kg/m^2. In the second two-way ANOVA, the women were grouped 
into low estradiol and high estradiol. The low estradiol group included women who had initial 
estradiol serum concentrations of 6 pg/mL or lower, while the high estradiol group included 
women who had initial estradiol serum concentrations of 6.1 pg/mL or higher. In the third two-
way ANOVA, the women were grouped based on age. The first group included women ages 45 
to 53 years old, while the second group included women ages 53.1 years old or older. They were 
additionally grouped into not responded and responded categories, as well, based on their HAI 
titer fold increase. Women with HAI titer fold increases of 4 or greater were categorized as 
having responded, while women with HAI titer fold increases of less than 4 were categorized as 
not having responded. The graphs are shown below: 
 
Figure 1. The graph above shows a two-way ANOVA test assessing the relationship between 
BMI and HAI titer antibody response. The p-value for the relationship between not 
responded:obese vs. responded:obese was 0.0313, indicating that there is significance between 
the difference in antibody response between those who responded and didn’t respond, but that 
obesity was not the cause of this significant difference. 
 
Figure 1. The graph above shows a two-way ANOVA test assessing the relationship between 
initial serum estradiol concentrations and HAI titer antibody response. The p-value for the 
relationship between not responded:low estradiol vs. responded:low estradiol was 0.0197, 
indicating that there is significance between the difference in antibody response between those 
who responded and didn’t respond, but that initial estradiol serum concentration was not the 
cause of this significant difference. 
 Since the two-way ANOVAs showed that neither BMI nor initial serum estradiol 
concentrations were the cause of the significant difference between the not responded and 
responded groups, a two-way ANOVA was also performed with age to assess if old age was the 
reason behind the significant difference in antibody response. This is shown below: 
 Figure 1. The graph above shows a two-way ANOVA test assessing the relationship between 
age and HAI titer antibody response. The p-value for the relationship between not responded:age 
53.1-60 years old vs. responded:age 53.1-60 years old was 0.0063, indicating that there is 
significance between the difference in antibody response between those who responded and 
didn’t respond, but that age was not the cause of this significant difference. 
 
 
Discussion 
 The primary consequence of menopause is a decline in estradiol levels which then causes 
various other consequences like a decline in immune function (Gameiro). A mouse model study 
done prior to this study by Nguyen et al showed that mice that were modeled to be post-
menopausal responded better to the flu vaccine after receiving hormone replacement therapy as 
opposed to not receiving hormone replacement therapy (Nguyen). When this study was begun 
1.5 years ago in the spring of 2016, it was the only human study to observe the relationship 
between estradiol and antibody response to the flu vaccine and was thus modeled after the 
Nguyen study.  
Measuring antibody response and estradiol concentrations 
 In order to assess the antibody response of the 24 women, indirect ELISA assays were 
conducted to study the amount of IgG total and IgG1 present in the sample, while HAI assays 
were conducted in order to study the amount of virus-specific antibody in the sample. These tests 
were run on the pre- and post-vaccination samples of the 24 women and the percent change of 
the IgG total and IgG1 data was calculated from the ELISA assays, while the fold increase of the 
HAI titer data was calculated from the HAI titers. In order to assess the estradiol concentrations 
present in the pre-vaccination sample, a competitive ELISA kit was used. 
Grouping the women 
 The women were initially grouped based on BMI category. The first group included 
women in the healthy weight category which was defined as having a BMI of 25 kg/m^2 or less. 
The second group included women in the overweight category which was defined as having a 
BMI between 25 kg/m^2 and 30 kg/m^2. The last group included women in the obese category 
which was defined as having a BMI greater than 30 kg/m^2. Using this system of grouping, a 
one-way ANOVA was run on the relationship between BMI and IgG total or IgG1 percent 
change/HAI titer fold increase in order to assess the significance. The women were additionally 
grouped into categories based on estradiol serum concentrations. Group 1 included women with 
estradiol serum concentrations of 0.0 to 3.0 pg/mL. Group 2 included women with estradiol 
serum concentratons of 3.1 to 8.0 pg/mL. Group 3 included women with estradiol serum 
concentrations of 8.1 pg/mL and above. Using this system of grouping, a one-way ANOVA was 
run on the relationship between estradiol serum concentration and IgG total or IgG1 percent 
change/HAI titer fold increase in order to assess the significance. A linear regression was also 
run on the estradiol concentrations and IgG total or IgG1 percent change/HAI titer fold increase 
without grouping in order to further assess the significance of the relationship. Lastly, two-way 
ANOVAs were also run in order to test the relationship between BMI and antibody response, 
estradiol concentrations and antibody response, and age and antibody response. For the two-way 
ANOVA, the women were this time categorized into obese versus nonobese, where obese 
women had BMI’s of 30kg/m^2 or greater and nonobese women had BMIs of less than 
30kg/m^2. The women were also grouped into low estradiol versus high estradiol, where low 
estradiol was categorized as 6.0 pg/mL or less and high estradiol was categorized as 6.1 pg/mL 
or greater. The women were further grouped by age, where the first group consisted of women 
ages 45 to 53 years old and the second group consisted of women ages 53.1 to 60 years old. In all 
three two-way ANOVAs, the women were additionally grouped into responsive versus 
nonresponsive to the flu vaccine. Nonresponsive was defined as having a HAI titer fold increase 
of less than 4, while responsive was defined as having a HAI titer fold increase of 4 or greater. 
Insignificance between BMI and antibody response 
 A one-way ANOVA was conducted to study the relationship between BMI and antibody 
response using the grouping system mentioned above. The p-value for the one-way ANOVA 
testing the relationship between BMI and IgG total percent change was 0.5102 with a R-square 
value of 0.06207, indicating no significance and no correlation. The p-value for the one-way 
ANOVA assessing the significance of the relationship between BMI and IgG1 percent change 
was found to be 0.1737 with a R-square value of 0.1535, indicating no significance and no 
correlation. The p-value for the one-way ANOVA assessing the relationship between BMI and 
HAI titer fold increase was found to be 0.6776 with a R-square value of 0.03639, indicating no 
significance and no correlation. This is unsupported by the literature.  
Insignificance between estradiol serum concentrations and antibody response 
 A two-way ANOVA was conducted to study the relationship between initial estradiol 
serum concentation and antibody response using the grouping system mentioned above. A linear 
regression was also run on the data, as well. The p-value found via the two-way ANOVA for 
estradiol serum concentration and IgG total mean percent change was found to be 0.1284 with a 
R-square value of 0.1776, indicating no significance and no correlation. The p-value found via 
the two-way ANOVA for estradiol serum concentration and IgG1 mean percent change was 
found to be 0.3417 with a R-square value of 0.0972, indicating no significance and no 
correlation. The p-value found via the two-way ANOVA for estradiol serum concentration and 
HAI titer fold increase was found to be 0.0765 with a R-square value of 0.2172, indicating no 
significance (though it is close) and no correlation. The p-value for the linear regression 
assessing the relationship between estradiol concentration and IgG total percent change was 
found to be 0.0586 with a R-square value of 0.1531, indicating no significance (though it is 
close) and no correlation. The p-value for the linear regression assessing the relationship between 
estradiol concentration and IgG1 percent change was found to be 0.5062 with a R-square value 
of 0.02034, indicating no significance (though it is close) and no correlation. The p-value for the 
linear regression assessing the relationship between estradiol concentration and HAI titer fold 
increase was found to be 0.1237 with a R-square value of 0.1043, indicating no significance 
(though it is close) and no correlation. This is unsupported by the literature. 
 
Significance between antibody response groups 
 A two-way ANOVA was also run to assess the relationship between estradiol 
concentrations and HAI titer fold increase grouped in the way described above and a p-value of 
0.0197 was found for the relationship between the not responded:low estradiol and 
responded:low estradiol, indicating significance between those who responded to the vaccine and 
those who did not respond to the vaccine. However, this also means that estradiol concentration 
is not the cause of the significance of the difference between the two groups. A two-way 
ANOVA was also run to assess the relationship between estradiol concentration and HAI titer 
fold increase grouped in the way described above and a p-value of 0.0313 was found for the 
relationship between the not responded:obese and responded:nonobese, indicating significance 
between those who responded to the vaccine and those who did not respond to the vaccine.  
Again, however, this also means that BMI is not the cause of the significance of the difference 
between the two groups.  A two-way ANOVA was also run to assess the relationship between 
age and HAI titer fold increase grouped in the way described above and a p-value of 0.0197 was 
found for the relationship between the not responded:45-53 years old and responded:53.1-60 
years old, indicating significance between those who responded to the vaccine and those who did 
not respond to the vaccine. However, this also means that age is not the cause of the significance 
of the difference between the two groups. 
 
 
Limitations 
 There were many limitations in this study. First, post-menopausal women have such low 
estradiol concentration levels that the ELISA kit used to measure the concentration in each 
sample may not have been sensitive enough to accurately measure the concentration in these 
specific women, since it measures such a wide range. Additionally, due to various technicalities 
and changes made throughout the study, the study only included 24 women. This is an extremely 
small sample size, which makes it very difficult to make significant conclusions. Additionally, 
post-menopausal women have very small differences in estradiol concentrations, so this study 
may have improved by comparing pre- and post-menopausal women’s antibody response to the 
flu vaccine.  
Conclusions and future studies 
 Since it has been shown that estradiol deprivation is the cause of numerous health 
declines (Gameiro et al. 2010), including antibody response to the flu vaccine (Nguyen), it 
follows that increasing estrogen or decreasing estrogen has an effect on antibody response to the 
flu vaccine. Therefore, this study studied the various estradiol concentrations in 24 women and 
compared that with their antibody response. It was hypothesized that women with higher levels 
of estradiol will have increased antibody response to the influenza vaccine as opposed to women 
with lower estradiol levels. However, obesity could also be affect antibody response in post-
menopausal women, since post-menopausal women are more susceptible to weight gain 
(Colombel et al. 1997). Since post-menopausal obese women have higher levels of estradiol as 
opposed to lean post-menopausal women, post-menopausal women with higher BMI’s will have 
an increased antibody response to the influenza vaccine as opposed to post-menopausal women 
with low BMIs.  
The hypothesis was proven incorrect. There was found to be no significance between 
BMI and antibody response nor between estradiol and antibody response, which does not agree 
with the hypothesis nor with the literature used to form the hypothesis and this study. Though the 
hypothesis could not be accepted, it is still possible that BMI and estradiol concentrations do 
indeed affect the antibody response to the flu vaccine. As mentioned above, the sample size was 
too small to make a significant conclusion and the ELISA kit used may have had too wide of a 
range to be accurate enough for the purposes of this study. Additionally, since post-menopausal 
women have very low estradiol levels, it may be difficult to find significance between their 
estradiol levels, as well. Thus, for future studies, I would suggest conducting this study with a 
larger sample size and by comparing estradiol levels in pre- and post-menopausal women. I 
would also suggest using an ELISA kit that has a more narrow range of measurement values.  
The influenza virus is responsible for numerous deaths and hospitalizations every year. 
The influenza virus vaccine is the primary source of protection against the virus. It is important 
to know who is most susceptible to the influenza virus, as well as who is most susceptible to not 
responding to the vaccine and why. This study, and future studies similar to this, could help 
improve the antibody response to the flu vaccine of numerous women across the world.  
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